Biodexa Pharmaceuticals PLC: February 2025 Form 6-K Financial Report Insights

Here are the key insights extracted from the financial report (Form 6-K) of Biodexa Pharmaceuticals PLC:

1. Filing Type and Date:

• This is a Form 6-K report submitted by Biodexa Pharmaceuticals PLC.
• The report is dated February 10, 2025.

2. Company Information:

• Name: Biodexa Pharmaceuticals PLC
• Address: 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

3. Commission File Number:

• The report references Commission File Number: 001-37652.

4. Annual Report Filing:

• The company indicates that it files annual reports under Form 20-F.

5. Exhibit Included:

• The report includes an attached Exhibit (Exhibit 99.1), which is a press release dated February 10, 2025.

6. Legal Disclaimers:

• The information in the attached Exhibit is being furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in any filing made under the Securities Act of 1933 or the Exchange Act, unless stated otherwise.

7. Signature:

• The report has been signed by Stephen Stamp, who holds the positions of Chief Executive Officer and Chief Financial Officer.

This document serves as a routine filing by a foreign private issuer and includes company disclosures relevant to investors and regulatory bodies.